SHREEKUMAR VINEKAR: Open Payments
NPI 1396713640 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$718 in 35 payments from 9 companies in 2025. Trend: 2023 $1,968 · 2024 $336 · 2025 $718
Food & beverage: $718
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 14 | $269 |
| Alkermes, Inc. | 7 | $136 |
| Almatica Pharma LLC | 4 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $64 |
| ABBVIE INC. | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
Products named: REXULTI, ARISTADA, LOREEV XR, CAPLYTA, VRAYLAR, AUSTEDO XR, ABILIFY ASIMTUFII, Quviviq.
Industry payments across OK — which companies pay providers there.
